life

MDPI

Systematic Review

Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis

José-Juan Pereyra-Rodriguez [1,2,*], Sara Alcantara-Luna [3], Javier Domínguez-Cruz [1], Manuel Galán-Gutiérrez [4], Ricardo Ruiz-Villaverde [5], Samuel Vilar-Palomo [6] and Jose-Carlos Armario-Hita [7]

Supplementary Materials

Figure S1. Analysis of risk of bias . a) Graph of risk of bias b) Summary of risk of bias ("between the studies"). The risk of bias analysis focused on the primary objectives of the systematic review (EASI 75/90).

Figure S2. Funnel Plot obtained in the NMA a) EASI 75 monotherapy; b) EASI 75 in combination with TCS; c) IGA 0/1 monotherapy; d) IGA 0/1 in combination with TCS.

Figure S3. Forest plot of the results of EASI 50 and 90 and NRS pruritus 0/1 obtained in the NMA in Monotherapy. ABRO100: Abrocitinib 100 mg daily; ABRO200: Abrocitinib 200 mg daily; BARI2: Baricitinib 2 mg daily; BARI4: Baricitinib 4 mg daily; DUPI300Q2W: Dupilumab 300 mg every other week; LEBRI250Q2W: Lebrokizumab 250 mg every other week; NEMO60Q4W: Nemolizumab 60 mg every 4 weeks; PBO: Placebo; TRALO300Q2W: Tralokinumab 300 mg every other week; UPA15: Upadacitinib 15 mg daily; UPA30: Upadacitinib 30 mg daily.

Figure S4. Forest plot of the results of EASI 50 and 90 and NRS pruritus 0/1 obtained in the NMA in combination with TCS. BARI2: Baricitinib 2 mg daily; BARI4: Baricitinib 4 mg daily; DUPI300Q2W: Dupilumab 300 mg every other week; LEBRI250Q2W: Lebrokizumab 250 mg every other week; NEMO60Q4W: Nemolizumab 60 mg every 4 weeks; PBO: Placebo; TEZE280Q2W: Tezepalumab 280 mg every other week; TRALO300Q2W: Tralokinumab 300 mg every other week; UPA15: Upadacitinib 15 mg daily; UPA30: Upadacitinib 30 mg daily.

Figure S5. Forest plot of safety results. a) At least one adverse effect in monotherapy; b) At least one adverse effect in combination with TCS; c) At least one severe adverse effect in monotherapy; d) At least one severe adverse effect in combination with TCS. BARI2: Baricitinib 2 mg daily; BARI4: Baricitinib 4 mg daily; DUPI300Q2W: Dupilumab 300 mg every other week; LEBRI250Q2W: Lebrokizumab 250 mg every other week; NEMO60Q4W: Nemolizumab 60 mg every 4 weeks; PBO: Placebo; TEZE280Q2W: Tezepalumab 280 mg every other week; TRALO300Q2W: Tralokinumab 300 mg every other week; UPA15: Upadacitinib 15 mg daily; UPA30: Upadacitinib 30 mg daily.

Table S1. Data extracted from the studies included in the NMA.

Table S2. SUCRA and probability of each drug for the different variables studied in the NMA.

Table S3. Separate indirect from direct evidence (SIDE) using back-calculation method.

Table S4. Supplementary material eTable 4. Studies excluded in the quantitative analysis, with the cause of exclusión.

Scheme. criptR: R-project program script used to run the meta análisis (TXT).

Records excluded after reading full text (Excel).

PRISMA NMA checklist (Word).